Chronic Diseases

Transforming the Management of Chronic Diseases with Biosimilars

Hugo Sotelo; Jorge Catella

Biosidus

Protein Degradation

PROTACS: Upgrading Small Molecule Inhibitors

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Clinical Trials

Optimizing Oncology and Rare Disease Clinical Trials by Focusing on Science and Aligning with both Patients and Investigators

Dave Selkirk

Ergomed

Vaccines

Delivering a Next-Generation COVID-19 Vaccine for Immunocompromised Patients and Novel Cancer Vaccines

David Dodd; Mark Newman, Ph.D.

GeoVax Inc.

Microbiome

Modifying the Gut Microbiome to Improve CAR-T, HSCT, and Other Therapeutic Responses

Stacy Burns-Guydish, Ph.D.

List Labs

Cell Therapy

Creating Efficiencies in Engineered Cell Therapy Development with Comprehensive Electroporation Support

Sarah Meeks, Ph.D.

MaxCyte

Oncology

Addressing Cancer Therapy Resistance by Targeting Translational Regulation

Steve Worland, Ph.D.

eFFECTOR

Tumor Microenvironment

Harnessing the Power of the Tumor Microenvironment with First-in-Class Therapies

Gil Efron

Purple Biotech

Bone Regeneration

A Novel Technology Platform for Bone Regeneration and Cancer Treatment

Denis Dufrane, M.D., Ph.D.

Collaboration

AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

Anima Biotech Inc.

Immuno-Oncology

Targeted Immune System Activation: A Paradigm Shift in Immuno-oncology

Dan Passeri, M.Sc., J.D.

Cue Biopharma

Column: New Drug Watch

Potential Applications for Antisense Oligonucleotide Therapies Continue to Expand

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Theranostics

Theranostic Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

Immuno-Oncology

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Derek Hennecke

Inceptor Bio

Oncology

Fighting Cancer and Supporting Patients

Gibson Oncology

Cancer Genetics

Developing RNA Screening for Cancer Diagnosis

Calviri